Nutrient Sensing in the Duodenum
| Status: | Enrolling by invitation |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 1/12/2019 |
| Start Date: | November 2012 |
| End Date: | December 2019 |
Duodenal Lipid Sensing and Nutrient Absorption
Preliminary studies in humans suggest that the presence of lipids in the gut can modify
glucose absorption. The overall hypothesis of this proposal is that long chain fatty acid
sensing in the duodenum has a significant role in modifying nutrient (glucose and amino acid)
absorption from the GI tract through a gut-brain-gut axis.
glucose absorption. The overall hypothesis of this proposal is that long chain fatty acid
sensing in the duodenum has a significant role in modifying nutrient (glucose and amino acid)
absorption from the GI tract through a gut-brain-gut axis.
The investigator will conduct a study in 20 lean (BMI = 19-27 kg/m2) subjects involving
intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid tracers
and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will allow
the investigators to determine if LCFA can alter nutrient absorption and glucose and amino
acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve
terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of
glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK,
GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs)
will be measured during all infusion periods.
intravenous (IV) and intraduodenal (ID) infusions of glucose tracers or amino acid tracers
and measurement of tracer rate of appearance in the plasma. An ID infusion of LCFA will allow
the investigators to determine if LCFA can alter nutrient absorption and glucose and amino
acid metabolism. Benzocaine will be added to the ID infusion of LCFA to inhibit nerve
terminals in the duodenum thereby preventing gut-brain communication. Plasma levels of
glucose and amino acid tracers, glucose oxidation (13CO2 breath test), gut hormones (CCK,
GIP, PYY, GLP-1, ghrelin), and bioactive lipids (N-acyl phosphatidylethanolamines, NAPEs)
will be measured during all infusion periods.
Inclusion Criteria:
- BMI = 19-27 kg/m2
- 30-55 years of age
Exclusion Criteria:
- Contraindication for nasal tube placement (e.g. deviated septum, prior upper
gastrointestinal bleed, or history of easy bleeding)
- Prior gastric or intestinal surgery or pancreas resection
- Females with a positive pregnancy test
- Known history of intestinal diseases including (but not limited to) inflammatory bowel
disease (e.g. ulcerative colitis, Crohn's disease), celiac sprue, Barrett's esophagus
- Type 1 or type 2 diabetes
- Gastroenteritis (diarrhea and/or vomiting) or constipation within the past week
We found this trial at
1
site
1211 Medical Center Dr
Nashville, Tennessee 37232
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
Click here to add this to my saved trials
